Aware of its important role in the entire chain of access to medicines and the incorporation of new technologies, in 2018, ABHH established the Committee on Access to Medicines. In the following three years, it promoted three Forums for discussion with the participation of all the actors involved in the process, such as medical societies, patients, industry and regulatory agencies to discuss, in addition to access, the incorporation of drugs and innovative technologies.
In addition, it is the mission of the ABHH Committee on Access to Medicines to monitor the shortage of essential drugs for onco-hematological treatments, both in public and supplementary health
In view of the proposed initiative, to be an active entity and facilitator in the process of access to medicines inserted in all discussion forums on the subject, especially those involving federal spheres, the ABHH called on specialists to act on this important front, paying attention to the national capillarity of professionals
It is the State's duty to ensure that information of public interest is made available in a clear, objective manner, easily accessible and in a language understandable to all citizens. It is in this context that the public consultation, mentioned in the Access to Information Act and which establishes access to public information based on the “holding of public hearings or consultations, encouraging popular participation or other forms of dissemination”, is inserted.
The 3 bodies below are responsible for regulating a new technology in Brazil and whenever this technology enters the ATS system, public consultations are open for the participation of society.
Stay tuned and participate whenever the topic is of interest to you!
The National Commission for the Incorporation of Technologies into the Unified Health System - SUS - Conitec, assisted by the Department of Management and Incorporation of Health Technologies - DGITS, aims to advise the Ministry of Health - MS on the attributions related to the incorporation, exclusion or alteration of health technologies by the SUS, as well as on the constitution or amendment of a clinical protocol and therapeutic guideline.
The National Supplementary Health Agency (ANS) is the regulatory agency linked to the Ministry of Health responsible for the health insurance sector in Brazil. The board of directors of the ANS is collegial, composed of 4 (four) directors and one (1) chief executive with inconsistent terms of office. As of the entry into force of Law No. 13,848, of June 25, 2019, the terms of office are non-coincidental and have a duration of five years, and reappointment is prohibited. The chief executive officer and directors are appointed by the President of the Republic, who specifies, in each case, whether the nomination is for chief executive or director, subject to approval by the Federal Senate, for subsequent appointment.
Joint official note — ABHH, SBTMO and Sobope warn of the shortage of melphalan in Brazil. Busilvex 6mg/ml (Busulfan, intravenous). Check out updates on the discontinuation of the drugs Alkeran Injectable 50 mg/10 mL vials and Busilvex 6mg/ml (Busulfan, intravenous)
